CN102329329A - 盐酸头孢甲肟化合物的新制法 - Google Patents
盐酸头孢甲肟化合物的新制法 Download PDFInfo
- Publication number
- CN102329329A CN102329329A CN 201110197613 CN201110197613A CN102329329A CN 102329329 A CN102329329 A CN 102329329A CN 201110197613 CN201110197613 CN 201110197613 CN 201110197613 A CN201110197613 A CN 201110197613A CN 102329329 A CN102329329 A CN 102329329A
- Authority
- CN
- China
- Prior art keywords
- cefmenoxime
- temperature
- cefmenoxime hemihydrochloride
- hemihydrochloride
- preferred
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960003791 cefmenoxime Drugs 0.000 title claims abstract description 53
- 238000000034 method Methods 0.000 title claims abstract description 50
- -1 cefmenoxime hydrochloride compound Chemical class 0.000 title claims abstract description 10
- MPTNDTIREFCQLK-UNVJPQNDSA-N cefmenoxime hydrochloride Chemical compound [H+].[Cl-].S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NN=NN1C.S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NN=NN1C MPTNDTIREFCQLK-UNVJPQNDSA-N 0.000 claims abstract description 111
- HJJDBAOLQAWBMH-YCRCPZNHSA-N cefmenoxime Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NN=NN1C HJJDBAOLQAWBMH-YCRCPZNHSA-N 0.000 claims abstract description 44
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 33
- 239000002904 solvent Substances 0.000 claims abstract description 28
- 238000002425 crystallisation Methods 0.000 claims abstract description 26
- 239000013078 crystal Substances 0.000 claims abstract description 22
- 239000002994 raw material Substances 0.000 claims abstract description 22
- 239000002253 acid Substances 0.000 claims abstract description 21
- 239000012065 filter cake Substances 0.000 claims abstract description 21
- 238000003756 stirring Methods 0.000 claims abstract description 21
- 230000008025 crystallization Effects 0.000 claims abstract description 20
- 238000001291 vacuum drying Methods 0.000 claims abstract description 20
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 235000011114 ammonium hydroxide Nutrition 0.000 claims abstract description 14
- 238000000967 suction filtration Methods 0.000 claims abstract description 10
- 239000012452 mother liquor Substances 0.000 claims abstract 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 40
- 230000008569 process Effects 0.000 claims description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 239000007864 aqueous solution Substances 0.000 claims description 21
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 20
- 229910021529 ammonia Inorganic materials 0.000 claims description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 15
- 239000010413 mother solution Substances 0.000 claims description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 3
- 238000000151 deposition Methods 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 239000000047 product Substances 0.000 abstract description 14
- 238000001914 filtration Methods 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 5
- 239000002244 precipitate Substances 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 238000005406 washing Methods 0.000 abstract description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 abstract 3
- 238000007605 air drying Methods 0.000 abstract 1
- 239000012535 impurity Substances 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 238000005227 gel permeation chromatography Methods 0.000 description 10
- 229920002521 macromolecule Polymers 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000004811 liquid chromatography Methods 0.000 description 5
- 238000004062 sedimentation Methods 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000005352 clarification Methods 0.000 description 4
- 229910001385 heavy metal Inorganic materials 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 229930186147 Cephalosporin Natural products 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229940124587 cephalosporin Drugs 0.000 description 3
- 150000001780 cephalosporins Chemical class 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- HSHGZXNAXBPPDL-HZGVNTEJSA-N 7beta-aminocephalosporanic acid Chemical compound S1CC(COC(=O)C)=C(C([O-])=O)N2C(=O)[C@@H]([NH3+])[C@@H]12 HSHGZXNAXBPPDL-HZGVNTEJSA-N 0.000 description 2
- AYDQIZKZTQHYIY-UHFFFAOYSA-N OC(=O)C1(C)CC(C(O)=O)=CC=C1 Chemical compound OC(=O)C1(C)CC(C(O)=O)=CC=C1 AYDQIZKZTQHYIY-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002932 luster Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- RXYOYKDBLLALFG-FAIYLGIWSA-M sodium;(6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NN=NN1C RXYOYKDBLLALFG-FAIYLGIWSA-M 0.000 description 2
- HZYJYGJIOCXOTH-FAIYLGIWSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrochloride Chemical compound Cl.S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NN=NN1C HZYJYGJIOCXOTH-FAIYLGIWSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
- 206010061695 Biliary tract infection Diseases 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Divinylene sulfide Natural products C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- ODFJOVXVLFUVNQ-UHFFFAOYSA-N acetarsol Chemical compound CC(=O)NC1=CC([As](O)(O)=O)=CC=C1O ODFJOVXVLFUVNQ-UHFFFAOYSA-N 0.000 description 1
- RMZZTJOADJVCIO-UHFFFAOYSA-N acetic acid;acetonitrile;hydrate Chemical compound O.CC#N.CC(O)=O RMZZTJOADJVCIO-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 230000003570 biosynthesizing effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000011003 system suitability test Methods 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 239000010331 tianhuang Substances 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/57—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with a further substituent in position 7, e.g. cephamycines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cephalosporin Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (9)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110197613 CN102329329B (zh) | 2011-07-15 | 2011-07-15 | 盐酸头孢甲肟化合物的制法 |
| PCT/CN2011/001331 WO2013010296A1 (zh) | 2011-07-15 | 2011-08-11 | 盐酸头孢甲肟化合物的新制法 |
| US14/008,542 US8895728B2 (en) | 2011-07-15 | 2011-08-11 | Method for preparing cefmenoxime hydrochloride compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110197613 CN102329329B (zh) | 2011-07-15 | 2011-07-15 | 盐酸头孢甲肟化合物的制法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102329329A true CN102329329A (zh) | 2012-01-25 |
| CN102329329B CN102329329B (zh) | 2012-09-05 |
Family
ID=45481315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110197613 Active CN102329329B (zh) | 2011-07-15 | 2011-07-15 | 盐酸头孢甲肟化合物的制法 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US8895728B2 (zh) |
| CN (1) | CN102329329B (zh) |
| WO (1) | WO2013010296A1 (zh) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103145735A (zh) * | 2013-03-21 | 2013-06-12 | 四川省惠达药业有限公司 | 一种注射用盐酸头孢甲肟化合物及其药物组合物 |
| CN104910189A (zh) * | 2015-06-16 | 2015-09-16 | 海南灵康制药有限公司 | 一种盐酸头孢甲肟新型工业结晶技术 |
| CN110526928A (zh) * | 2019-09-17 | 2019-12-03 | 河北科技大学 | 一种7-氨基去乙酰氧基头孢烷酸的精制方法 |
| CN112661776A (zh) * | 2020-12-29 | 2021-04-16 | 苏州盛达药业有限公司 | 一种盐酸头孢甲肟的制备方法 |
| CN114113359A (zh) * | 2021-05-07 | 2022-03-01 | 佛山市南海北沙制药有限公司 | 一种7-aca衍生物的中控检测方法 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111024847B (zh) * | 2019-12-24 | 2022-03-01 | 河北合佳医药科技集团股份有限公司 | 一种柱前衍生化法测定ae-活性酯纯度的方法 |
| CN118724919A (zh) * | 2024-06-04 | 2024-10-01 | 艾美科健(中国)生物医药有限公司 | 头孢维星钠双侧链杂质的制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101569628A (zh) * | 2009-06-19 | 2009-11-04 | 山东罗欣药业股份有限公司 | 一种盐酸头孢甲肟组合物粉针及其制备方法 |
| CN101798314A (zh) * | 2010-03-24 | 2010-08-11 | 海南数尔药物研究有限公司 | 一种高纯度的盐酸头孢甲肟化合物 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101550150B (zh) * | 2009-05-07 | 2010-12-29 | 张锡芬 | 一种头孢甲肟化合物及其合成方法 |
-
2011
- 2011-07-15 CN CN 201110197613 patent/CN102329329B/zh active Active
- 2011-08-11 US US14/008,542 patent/US8895728B2/en not_active Expired - Fee Related
- 2011-08-11 WO PCT/CN2011/001331 patent/WO2013010296A1/zh not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101569628A (zh) * | 2009-06-19 | 2009-11-04 | 山东罗欣药业股份有限公司 | 一种盐酸头孢甲肟组合物粉针及其制备方法 |
| CN101798314A (zh) * | 2010-03-24 | 2010-08-11 | 海南数尔药物研究有限公司 | 一种高纯度的盐酸头孢甲肟化合物 |
Non-Patent Citations (1)
| Title |
|---|
| 《山东化工》 20071231 汪东海 等 盐酸头孢甲肟合成工艺的改进 19-21 第36卷, 第12期 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103145735A (zh) * | 2013-03-21 | 2013-06-12 | 四川省惠达药业有限公司 | 一种注射用盐酸头孢甲肟化合物及其药物组合物 |
| CN103145735B (zh) * | 2013-03-21 | 2014-02-26 | 四川省惠达药业有限公司 | 一种注射用盐酸头孢甲肟化合物及其药物组合物 |
| CN104910189A (zh) * | 2015-06-16 | 2015-09-16 | 海南灵康制药有限公司 | 一种盐酸头孢甲肟新型工业结晶技术 |
| CN104910189B (zh) * | 2015-06-16 | 2016-01-20 | 海南灵康制药有限公司 | 一种盐酸头孢甲肟的工业结晶方法 |
| CN110526928A (zh) * | 2019-09-17 | 2019-12-03 | 河北科技大学 | 一种7-氨基去乙酰氧基头孢烷酸的精制方法 |
| CN112661776A (zh) * | 2020-12-29 | 2021-04-16 | 苏州盛达药业有限公司 | 一种盐酸头孢甲肟的制备方法 |
| CN114113359A (zh) * | 2021-05-07 | 2022-03-01 | 佛山市南海北沙制药有限公司 | 一种7-aca衍生物的中控检测方法 |
| CN114113359B (zh) * | 2021-05-07 | 2024-02-20 | 佛山市南海北沙制药有限公司 | 一种7-aca衍生物的中控检测方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102329329B (zh) | 2012-09-05 |
| US8895728B2 (en) | 2014-11-25 |
| WO2013010296A1 (zh) | 2013-01-24 |
| US20140121370A1 (en) | 2014-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102329329B (zh) | 盐酸头孢甲肟化合物的制法 | |
| CN102268019B (zh) | 一种头孢羟氨苄化合物及其制法 | |
| CN102190667B (zh) | 一种纯化盐酸头孢替安的制法 | |
| CN101613359B (zh) | 头孢呋辛钠合成方法 | |
| CN101584671A (zh) | 一种头孢西酮钠药物粉针剂以及头孢西酮钠原料药的合成方法 | |
| CN103757085B (zh) | 头孢克洛及其合成方法 | |
| CN102180892A (zh) | 一种纯化头孢美唑钠的新方法 | |
| CN102086196B (zh) | 一种氨曲南的方法 | |
| CN1142938C (zh) | 制备头孢丙肟酯非对映异构体的方法 | |
| CN102329328B (zh) | 一种纯化头孢唑肟钠化合物的新方法 | |
| CN102268025A (zh) | 一种比阿培南化合物及其制法 | |
| CN102796116B (zh) | 一种高纯度头孢唑肟钠的制备方法 | |
| CN117088896A (zh) | 一种盐酸头孢噻呋的精制方法 | |
| CN104130272A (zh) | 一种头孢氨苄合成工艺改进方法 | |
| CN104341435A (zh) | 头孢曲松钠的精制方法 | |
| CN102617327B (zh) | 右旋布洛芬化合物及其制法 | |
| CN102329313B (zh) | 一种盐酸阿扎司琼化合物及其制法 | |
| CN112679524B (zh) | 一种头孢曲松钠的制备方法 | |
| CN105646534A (zh) | 一种采用粒子过程晶体产品分子组装与形态优化技术的头孢硫脒新晶型化合物及制剂 | |
| CN106749410B (zh) | 一种高收率头孢洛林酯的制备方法 | |
| CN105646545A (zh) | 一种减少过敏反应的头孢美唑钠及其制剂 | |
| CN104910190A (zh) | 一种头孢替安二盐酸盐的制备方法 | |
| CN115043891B (zh) | 化合物及其制备方法和用途 | |
| CN103588787A (zh) | 一种头孢米诺钠晶体及其制备方法与应用 | |
| CN110343120B (zh) | 一种3-甲基头孢地尼的制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20130813 Address after: 570216 Hainan Province, Haikou city Jinpan Industrial Development Zone Industrial Village No. 3-6 building Patentee after: Hainan Lingkang Pharmaceutical Co., Ltd. Address before: 570216 No. 8 workshop, Haikou Free Trade Zone, Hainan Patentee before: Hainan Lingkang Pharmaceutical Co., Ltd. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20170602 Address after: The 856100 Tibet autonomous region, the city is Zedang Town Road No. 68 Naidong County Building second building a layer of Patentee after: Ling Kang Pharmaceutical Group Limited by Share Ltd Address before: 570216 Hainan Province, Haikou city Jinpan Industrial Development Zone Industrial Village No. 3-6 building Patentee before: Hainan Lingkang Pharmaceutical Co., Ltd. |
|
| TR01 | Transfer of patent right |